Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population
- PMID: 34706716
- PMCID: PMC8549212
- DOI: 10.1186/s12944-021-01568-9
Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) has been entitled as metabolic-dysfunction associated fatty liver disease (MAFLD). Therefore anthropometric indicators of adiposity may provide a non-invasive predictive and diagnostic tool for this disease. This study intended to validate and compare the MAFLD predictive and diagnostic capability of eight anthropometric indicators.
Methods: The study involved a population-based retrospective cross-sectional design. The Fangchenggang area male health and examination survey (FAMHES) was used to collect data of eight anthropometric indicators, involving body mass index (BMI), waist-to-height ratio (WHtR), waist-hip ratio (WHR), body adiposity index (BAI), cardiometabolic index (CMI), lipid accumulation product (LAP), visceral adiposity index (VAI), and abdominal volume index (AVI). Receiver operating characteristics (ROC) curves and the respective areas under the curves (AUCs) were utilized to compare the diagnostic capacity of each indicator for MAFLD and to determine the optimal cutoff points. Binary logistic regression analysis was applied to identify the odds ratios (OR) with 95% confidence intervals (95% CI) for all anthropometric indicators and MAFLD. The Spearman rank correlation coefficients of anthropometric indicators, sex hormones, and MAFLD were also calculated.
Results: All selected anthropometric indicators were significantly associated with MAFLD (P < 0.001), with an AUC above 0.79. LAP had the highest AUC [0.868 (95% CI, 0.853-0.883)], followed by WHtR [0.863 (95% CI, 0.848-0.879)] and AVI [0.859 (95% CI, 0.843-0.874)]. The cutoff values for WHtR, LAP and AVI were 0.49, 24.29, and 13.61, respectively. WHtR [OR 22.181 (95% CI, 16.216-30.340)] had the strongest association with MAFLD, regardless of potential confounders. Among all the anthropometric indicators, the strongest association was seen between LAP and sex hormones.
Conclusion: All anthropometric indicators were associated with MAFLD. WHtR was identified as the strongest predictor of MAFLD in young Chinese males, followed by LAP and AVI. The strongest association was found between LAP and sex hormones.
Keywords: Abdominal volume index; Anthropometric indicator; Lipid accumulation product; Metabolic-dysfunction associated fatty liver disease; Non-alcoholic fatty liver disease; Visceral fat; Waist-to-height ratio.
© 2021. The Author(s).
Conflict of interest statement
The authors have declared no potential conflicts of interest exist.
Figures
Similar articles
-
The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.Front Endocrinol (Lausanne). 2022 Nov 4;13:977625. doi: 10.3389/fendo.2022.977625. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36407325 Free PMC article.
-
Comparison of the predictive value of anthropometric indicators for the risk of benign prostatic hyperplasia in southern China.Asian J Androl. 2023 Mar-Apr;25(2):265-270. doi: 10.4103/aja202249. Asian J Androl. 2023. PMID: 36018066 Free PMC article.
-
Comparison of visceral, general and central obesity indices in the prediction of metabolic syndrome in maintenance hemodialysis patients.Eat Weight Disord. 2020 Jun;25(3):727-734. doi: 10.1007/s40519-019-00678-9. Epub 2019 Apr 9. Eat Weight Disord. 2020. PMID: 30968371
-
Waist to height ratio in nonalcoholic fatty liver disease - Systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2023 Aug;47(7):102160. doi: 10.1016/j.clinre.2023.102160. Epub 2023 Jun 14. Clin Res Hepatol Gastroenterol. 2023. PMID: 37321322 Review.
-
Accuracy of different cutoffs of the waist-to-height ratio as a screening tool for cardiometabolic risk in children and adolescents: A systematic review and meta-analysis of diagnostic test accuracy studies.Obes Rev. 2022 Feb;23(2):e13375. doi: 10.1111/obr.13375. Epub 2021 Nov 8. Obes Rev. 2022. PMID: 34751482 Review.
Cited by
-
LASSO-derived model for the prediction of lean-non-alcoholic fatty liver disease in examinees attending a routine health check-up.Ann Med. 2024 Dec;56(1):2317348. doi: 10.1080/07853890.2024.2317348. Epub 2024 Feb 16. Ann Med. 2024. PMID: 38364216 Free PMC article.
-
Development and validation of a nomogram for predicting metabolic-associated fatty liver disease in the Chinese physical examination population.Lipids Health Dis. 2023 Jun 29;22(1):85. doi: 10.1186/s12944-023-01850-y. Lipids Health Dis. 2023. PMID: 37386566 Free PMC article.
-
Chinese Visceral Adipose Index Shows Superior Diagnostic Performance in Predicting the Risk of Metabolic Dysfunction Associated Fatty Liver Disease in Early Postmenopausal Chinese Women.Diabetes Metab Syndr Obes. 2023 Mar 6;16:607-617. doi: 10.2147/DMSO.S402814. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 36909348 Free PMC article.
-
The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.Front Endocrinol (Lausanne). 2022 Nov 4;13:977625. doi: 10.3389/fendo.2022.977625. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36407325 Free PMC article.
-
Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults.Front Endocrinol (Lausanne). 2022 Sep 16;13:1004855. doi: 10.3389/fendo.2022.1004855. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36187093 Free PMC article.
References
-
- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
-
- Lee SJ, Kim SU. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13(6):523–530. doi: 10.1080/17474124.2019.1608820. - DOI - PubMed
-
- Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VWS, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi: 10.1016/S2468-1253(19)30039-1. - DOI - PubMed
MeSH terms
Grants and funding
- 2018YFC1314104/National Key Research & Development Projects
- 2017GXNSFAA198097/Natural Science Foundation of Guangxi Province
- 16-380-54, 17-259-45, 19-050-22, 19-185-33, 20-065-33/Guangxi key Laboratory for Genomic and Personalized Medicine
- 2017YFC0908000/National Key Research and Development Program of China
- AA18118016/Major Project of Guangxi Innovation Driven
LinkOut - more resources
Full Text Sources
Medical
Research Materials
